Skip to main content
Clinical Trials/NCT04598074
NCT04598074
Not Yet Recruiting
N/A

The Feasibility and Effectiveness of an Opioid Package Prototype (OPP) to Impact Opioid Prescribing, Dispensing, and Patient Use Outcomes

UConn Health1 site in 1 country352 target enrollmentSeptember 7, 2025

Overview

Phase
N/A
Intervention
Not specified
Conditions
Opioid Use
Sponsor
UConn Health
Enrollment
352
Locations
1
Primary Endpoint
Number of tablets of oxycodone prescribed
Status
Not Yet Recruiting
Last Updated
7 months ago

Overview

Brief Summary

The overall objective of this clinical trial is to identify the impact of selected package features, known as the Opioid Package Prototype (OPP), on the safe and effective use of opioids. Our specific aims are: (Aim 1) to evaluate the effectiveness of OPP on prescribing, dispensing, and patient use of oxycodone among orthopaedic surgery patients receiving post-operative outpatient oxycodone for post-surgical pain management, and (Aim 2) to determine the feasibility of OPP for orthopaedic surgery prescribers, pharmacists, and orthopaedic surgery patients. Such data can be used to further optimize packaging and labeling design, help patients and caregivers utilize their medication and packaging correctly, and improve prescribing and dispensing habits. The central hypothesis is that the OPP will be more effective than the amber vial in efforts to reduce oxycodone prescribing among patients over 18 receiving short-term management of post orthopedic surgery pain.

Registry
clinicaltrials.gov
Start Date
September 7, 2025
End Date
September 30, 2026
Last Updated
7 months ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Sponsor
UConn Health
Responsible Party
Principal Investigator
Principal Investigator

Nathaniel Rickles

Professor of Pharmacy Practice

UConn Health

Eligibility Criteria

Inclusion Criteria

  • The patient is 18 years and older;
  • The patient is one of the participating surgeons;
  • The patient is receiving orthopaedic surgery that involves the use of opioid medication for post-operative pain;
  • The patient is willing to receive oxycodone medication;
  • The patient is willing and able to receive medication at the UConn Health Specialty Pharmacy, located in the Exchange across the street from the main entrance of UConn Health;
  • The patient is willing and able to use a MyChart account;
  • The patient is able to read and understand English; and
  • The patient is able to understand the study procedures and their involvement in the study.

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Number of tablets of oxycodone prescribed

Time Frame: 3 months after surgery

Count via medical/pharmacy records

Average morphine milligram equivalent (MME) of oxycodone tablets prescribed/per participant

Time Frame: 3 months after surgery

Mean

Number of oxycodone tablets used by study participants

Time Frame: 3 months after surgery

Count via survey/interview/visual inspection/photograph

Average morphine milligram equivalent (MME) of oxycodone tablets used/per participant

Time Frame: 3 months after surgery

Mean

Secondary Outcomes

  • Amount of dispensing time per oxycodone prescription for each study participant(Time of surgery and any refills up to 1 month after surgery)
  • Amount of counseling time per oxycodone prescription for each study participant(Time of surgery and any refills up to 1 month after surgery)
  • Awareness of oxycodone medication information(1 week and 1 month after surgery)
  • Awareness of oxycodone tablets used(1 week and 1 month after surgery)
  • SANE (Single Assessment Numeric Evaluation) score(Baseline, 1 week, 1 month and 3 months after surgery)
  • PEG (Pain, Enjoyment of Life and General Activity) score(Baseline, 1 week, 1 month and 3 months after surgery)
  • Feasibility of OPP for orthopaedic surgery prescribers(Within 1 month after prescribing the OPP to 30 participants)
  • Feasibility of OPP for pharmacists(After dispensing all OPPs (approximately 2 years))
  • Peri-Operative Opioid-Related Symptom Distress Scale (OR-SDS)(1 week, 1 month and 3 months after surgery)
  • Number of requests for additional oxycodone prescriptions(1 week, 1 month and 3 months after surgery)
  • Change in knowledge of oxycodone from baseline to 1 week(Baseline (before surgery) and 1 week after surgery)
  • Consistency of access to oxycodone medication information(1 week and 1 month after surgery)
  • Pain Catastrophizing Scale (PCS)(Baseline, 1 week, 1 month and 3 months after surgery)
  • Pain Medication Attitudes Questionnaire (PMAQ-14) score(Baseline, 1 week, 1 month and 3 months after surgery)
  • Patient Health Questionnaire-4 (PHQ-4)(Baseline, 1 week and 1 month after surgery)
  • Feasibility of OPP for orthopaedic surgery patients(Between 1 and 3 months after surgery)

Study Sites (1)

Loading locations...

Similar Trials